CD98 as a novel prognostic indicator for patients with stage III/IV hypopharyngeal squamous cell carcinoma

Head and Neck

Volumn 37, Issue 11, 2015, Pages 1569-1574

  Toyoda, Miroru ^a   Kaira, Kyoichi ^a   Shino, Masato ^a   Sakakura, Koichi ^a   Takahashi, Katsumasa ^a   Takayasu, Yukihiro ^a   Tominaga, Hideyuki ^a   Oriuchi, Noboru ^b   Nikkuni, Osamu ^a,c   Suzuki, Masami ^c   Iijima, Misa ^c   Tsukamoto, Norifumi ^a   Nagamori, Shushi ^d   Kanai, Yoshikatsu ^d   Oyama, Tetsunari ^a   Chikamatsu, Kazuaki ^a  

^a GUNMA UNIVERSITY HOSPITAL   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c GUNMA PREFECTURAL CANCER CENTER   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

CD98; hypopharynx; immunohistochemistry; L type amino acid transporter 1 (LAT1); prognostic factor

Indexed keywords

AMINO ACID TRANSPORTER; CD98 ANTIGEN; CISPLATIN; DOCETAXEL; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; KI 67 ANTIGEN; L TYPE AMINO ACID TRANSPORTER 1; PROTEIN P53; TEGAFUR; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; ANALYSIS OF VARIANCE; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; HYPOPHARYNGEAL NEOPLASMS; IMMUNOHISTOCHEMISTRY; JAPAN; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR INVASION;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGENS, CD98; BIOMARKERS, TUMOR; BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOPHARYNGEAL NEOPLASMS; IMMUNOHISTOCHEMISTRY; JAPAN; KAPLAN-MEIER ESTIMATE; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84944160659     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23797     Document Type: Article

References (25)

1. Ragin CC, Modugno F, Gollin SM,. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 2007; 86: 104-114.
2. Thephamongkhol K, Browman G, Hodson I, Oliver T, Zuraw L, members of the Head and Neck Cancer Disease Site Group Chemotherapy with Radiotherapy for Nasopharyngeal Cancer: a clinical practice guideline evidence-based series #5-7. Toronto, ON: Cancer Care Ontario, Program in Evidence-Based Care; 2004.
3. Christensen HN,. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 1990; 70: 43-77.
4. McGivan JD, Pastor-Anglada M,. Regulatory and molecular aspects of mammalian amino acid transport. Biochem J 1994; 299 (Pt 2): 321-334.
5. Kanai Y, Segawa H, Miyamoto KI, Uchino H, Takeda E, Endou H,. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998; 273: 23629-23632.
6. Yanagida O, Kanai Y, Chairoungdua A, et al., Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001; 1514: 291-302.
7. Kobayashi H, Ishii Y, Takayama T,. Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol 2005; 90: 233-238.
8. Kaira K, Oriuchi N, Imai H, et al., Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 2008; 98: 742-748.
9. Nakanishi K, Ogata S, Matsuo H, et al., Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch 2007; 451: 681-690.
10. Nawashiro H, Otani N, Shinomiya N, et al., L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 2006; 119: 484-492.
11. Sakata T, Ferdous G, Tsuruta T, et al., L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int 2009; 59: 7-18.
12. Ichinoe M, Mikami T, Yoshida T, et al., High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathol Int 2011; 61: 281-289.
13. Furuya M, Horiguchi J, Nakajima H, Kanai Y, Oyama T,. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci 2012; 103: 382-389.
14. Kaira K, Oriuchi N, Takahashi T, et al., LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am J Transl Res 2011; 3: 468-478.
15. Kaira K, Sunose Y, Arakawa K, et al., Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer 2012; 107: 632-638.
16. Park NS, Kim SG, Kim HK, et al., Characterization of amino acid transport system L in HTB-41 human salivary gland epidermoid carcinoma cell. Anticancer Res 2008; 28: 2649-2655.
17. Kim CH, Park KJ, Park JR, et al., The RNA interference of amino acid transporter LAT1 inhibits the growth of KB human oral cancer cells. Anticancer Res 2006; 26: 2943-2948.
18. Devés R, Boyd CA,. Surface antigen CD98(4F2): not a single membrane protein, but a family of proteins with multiple functions. J Membr Biol 2000; 173: 165-177.
19. Cantor JM, Ginsberg MH,. CD98 at the crossroads of adaptive immunity and cancer. J Cell Sci 2012; 125 (Pt 6): 1373-1382.
20. Feral CC, Nishiya N, Fenczik CA, Stuhlmann H, Slepak M, Ginsberg MH,. CD98hc (SLC3A2) mediates integrin signaling. Proc Natl Acad Sci U S A 2005; 102: 355-360.
21. Kaira K, Oriuchi N, Imai H, et al., CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. Ann Surg Oncol 2009; 16: 3473-3481.
22. Kaira K, Oriuchi N, Imai H, et al., Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer 2009; 66: 120-126.
23. Rietbergen MM, Martens-de Kemp SR, Bloemena E, et al., Cancer stem cell enrichment marker CD98: a prognostic factor survival in patients with human papillomavirus-positive oropharyngeal cancer. Eur J Cancer 2014; 50: 765-773.
24. Martens-de Kemp SR, Brink A, Strigter-van Walsum M, et al., CD98 marks a subpopulation of head and neck squamous cell carcinoma cells with stem cell properties. Stem Cell Res 2013; 10: 477-488.
25. Kaira K, Oriuchi N, Imai H, et al., L-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci 2008; 99: 2380-2386.